Lipigon Q2 2025 - Last Patient In

Redeye comments on Lipigon’s Q2 report. At the end of June, the company recruited the last patient to the phase II study of Lipisense. The study is fully funded and the preliminary readout in Q4 2025 will be a major catalyst.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/